Xylem (XYL) Tops Q3 EPS by 1c, Beats on Revenues; Boosts FY17 EPS/Revenue Mid-Point Outlook Above Consensus

Go back to Xylem (XYL) Tops Q3 EPS by 1c, Beats on Revenues; Boosts FY17 EPS/Revenue Mid-Point Outlook Above Consensus

Xylem (XYL) PT Raised to $75 at Oppenheimer Following 3Q

November 1, 2017 9:30 AM EDT

Oppenheimer raised its price target on Xylem (NYSE: XYL) to $75.00 (from $66.00) while maintaining a Outperform rating following 3Q report. XYL reported adjusted 3Q17 EPS of $0.65, above consensus of $0.63E given strength in WI. Organic revenues increased 7% y/y despite tough comps.

The 3Q beat,... More